$GILD Tale of the Tape


Gilead Sciences (GILD) Stock: 3 Reasons Why It Is a Top Choice for Growth Investors – Tale of the Tape

Finding a great growth stock can be a tough task. Not only are there a wide range of choices, but the space can be extremely volatile and fraught with risk as well. But thanks to our new style score system we have been able to identify a few growth stocks which have incredible potential in the near term.

One such company that stands out in this regard is undoubtedly Gilead Sciences Inc. ( GILD). Not only does this company have a favorable growth score, but it is ranked as a buy too. And while there are numerous reasons why GILD is so attractive right now, we have highlighted three of the most important—and pertinent to growth investors—below:

Earnings Growth for GILD

Arguably nothing is more important than earnings growth as surging profit levels is what most investors are after. And for growth investors, earnings growth in the double digits is definitely necessary and it is often an indication of strong prospects (and stock price gains) ahead for the company in question.

While GILD has put up a historical EPS growth rate of 34.06%, investors should really focus on the projected growth. Here, GILD is looking to grow at a rate of 39.6%, thoroughly crushing the industry average which calls for EPS growth of just 5.5% in comparison.

Cash Flow Growth for GILD

Cash is the lifeblood of any business, but especially so for growth oriented companies. A positive figure here indicates that cash is flowing into the business (obviously a good thing), while a negative reading here means that net cash is exiting the company.

Right now, GILD’s current cash flow growth is an impressive 289.7%, a level that is far higher than many of its peers, and the industry average. In fact, the industry average sees cash flow growth of just 18% in comparison, suggesting that GILD is a better pick from a cash flow look.

GILD Earnings Estimate Revisions Moving in the Right Direction

If the metrics outlined above weren’t enough investors should also consider the positive trends that we are seeing on the analyst estimate revision front. Analysts have been raising their estimates for Gilead Sciences lately, and now the earnings picture is looking a bit more favorable for the company.

Over the past 60 days 1 EPS estimate has been revised higher compared to none lower, at least for the current year time frame. And the magnitude of these revisions has also been impressive, as the consensus estimate for the full year has surged from $10.64 per share to $11.04 per share today.


Please enter your comment!
Please enter your name here